Product Permission Document (PPD) of Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) I.P.

Brand Name: Quadri Meningo™

1. Introduction:

Meningococcal disease is a serious infection caused by a bacteria. Meningococcal bacteria can infect the blood, spinal cord, and brain. These conditions can be fatal.

Meningococcal disease can spread from one person to another through small droplets of saliva that are expelled into the air when an infected person coughs or sneezes. The bacteria can also be passed through contact with objects the infected person has touched, such as a door handle, or other surface. The bacteria can also be passed through kissing, or sharing a drinking glass or eating utensil with an infected person.

Meningococcal polysaccharide vaccine is used to prevent infection caused by meningococcal bacteria. The vaccine contains four of the most common types of meningococcal bacteria.

The bacterium Neisseria meningitidis, the meningococcus, is a Gram-negative, oxidase-positive diplococcus, identical in its staining and morphological characteristic to Neisseria gonorrhoeae. However, at an ultrastructural level, Neisseria meningitidis has a prominent polysaccharide capsule not seen in the gonococcus. The capsule is antiphagocytic and is an important virulence factor in meningococcal disease. Neisseria meningitidis strains are grouped on the basis of their capsular polysaccharide.

The capsular polysaccharide of Neisseria meningitidis are attractive vaccine candidates because they constitute the most highly conserved and most exposed bacteria-surface antigens. The use of capsular polysaccharide as immunoprophylactic agents against human disease caused by encapsulated bacteria is now firmly established. The capsular polysaccharides of the meningococcus are negatively charged and the obtained in a high molecular weight immunogenic form by precipitation. Meningococcal polysaccharide vaccines are efficacious to protect from meningitis disease in adults, but cannot provide full protection to infants under the age of 5. The duration of protection elicited by the meningococcal polysaccharide vaccine is not long lasting in adults and children above four years of age. For children from one to four years old the duration of protection is less than three years. Protective immunity to encapsulated bacterial pathogens such as Neisseria meningitidis principally mediated by the reaction between antibody and capsular polysaccharide epitopes. In encapsulated gram negative bacteria, protection results primarily from a direct complement-mediated bactericidal effect. Vaccines have been prepared from the capsular polysaccharide of Neisseria meningitidis (Group A, C, Y & W135). These and other polysaccharides have
been classified as T cell independent type 2 (TI-2) antigens based on their inability to stimulate an immune response in animals that carry an X-linked immune B-cell defect (xid). TI-2 antigens tend to be characterized by high molecular weight, multiple repeat epitopes, slow degradations in vivo, and a failure to stimulate major histocompatibility complex (MHC) type II mediated T-cell help. TI-2 antigens generally are incapable of stimulating an immune response in neonatal humans under 18 months of age. This has spurred attempts to modify the capsular polysaccharide such that vaccines protective for all at-risk groups will result. To date, the most successful approach has been to covalently bind carrier proteins to the polysaccharides, this engendering a vaccine capable of invoking a T-dependent response.

1.1. Submission file :-

The Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) is licensed on license No. 05/LVP/sera & vaccine/2004 on form 28D.

1.2. NDS Approval date and control :-


1.3. PPD –Biological revision date and control :-

PPD Biological Rev 02, dated 14/01/2015.

1.4. Proprietary Name:-

Quadri Meningo™.

1.5. Non Proprietary name and common name of drug substance:-

Purified Polysaccharide of Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) I.P.

1.6. Company Name :-

BIO-MED (P) LTD.
C-96, Site No. 1, Bulandshahr Road Industrial Area, Ghaziabad - 201 009 (U.P.) INDIA
Phone : 0120-4157534, 4204862
Fax : 0120-4340219
e-Mail : bmvaccine@yahoo.com
Website: www.biomed.co.in

1.7. Name of Indian Distributer/Agent :-

Not Applicable as we are indigenous manufacturer of vaccine.

1.8. Therapeutic or Pharmacological classification :-
1.9. **Dosage form(s):**

Reconstitute the freeze-dried lyophilysate, immediately prior to use with entire content of diluent (sodium chloride injection I.P.) provided with the vaccine, shake until lyophilysate is dissolved completely.

1.10. **Strength(s):**

Each dose (0.5 ml) of vaccine contains:

- Purified Polysaccharide of Neisseria meningitidis
  - Group A……………………………………………………………50 mcg
  - Group C…………………………………………………   ………50 mcg
  - Group Y……………………………………………………………50 mcg
  - Group W135………………………………………………………50 mcg
  - Lactose I.P. (Stabilizer) ………………………………………… 5 mg

1.1. **Route of Administration:**

Administer the vaccine (0.5 ml) by intramuscular or subcutaneous route.

1.2. **Maximum Daily Dose:**

Not Applicable

2. **New Active Substance (NAS):**

Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) is produced in all over the world for several decades. There are predefined parameters for the manufacturing of Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135). All the products used in the production of vaccine is already known. Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) is produced by Bio-Med (P) Ltd. All excipients used have been previously used for manufacture of human vaccine(s). None of the excipients are novel.

S. **Drug substance, name & manufacturer:**

S.1 **Manufacturer (name, manufacturer) and address:**

S.1.1 **Manufacturer(s) (name, manufacturer):**

BIO-MED (P) LTD.
C-96, Site No. 1,
Bulandshahr Road Industrial Area,
Ghaziabad - 201 009 (U.P.) INDIA
Phone : 0120-4157534, 4204862
Fax : 0120-4340219
e-Mail : bmvaccine@yahoo.com
Website: www.biomed.co.in
S.1.2. **Description of manufacturing process & process control:**

Seed propagation and establishment of working seed lot (freeze dried). Stored at or below -20°C. Passage level – P1

Preparation of precultures from working seed lot for inoculums for fermenter. (20 ml, 250 ml, 5000 ml)

Fermenter culture (110 liters), Passage level – P5

Harvesting and inactivation by adding formalin (0.5%)

Bacterial cell separation by continuous flow centrifugation

Precipitation of polysaccharide from culture supernatant by addition of 0.2% cetavalone

Dissociation of polysaccharide –cetavalone complex

Purification of polysaccharide by ethanol precipitation, cold phenol extraction

Purified polysaccharide lot (Store at or below – 20°C)

Bacterial purity, identification by microscopic examination of Gram’s stained smears (at least 10,000 organisms are inspected), motility test.

- Culture media sterility
- pH control
- Dissolved oxygen control
- Temperature control
- Rotation speed control
- Control of bacterial purity

By microscopic examination of Gram's stained smears (at least 10,000 organisms are inspected), motility test, inoculation into solid media. Control of bacterial inactivation.

Control of centrifugation speed.

- pH control
- Temperature control
- Control of centrifugation speed.
- Temperature control
- Control of centrifugation speed.
- Temperature control

- Moisture content
- Protein content
- Nucleic acid content
- O-acetyl content
- Molecular size
- Identity
- Sialic Acid Content
- Phosphorus Content
- pH
- Sterility test
- Free formaldehyde
- Cetrimeide
- Calcium content
- Pyrogens

S.1.3. **Control of materials:**

As discussed in the point No. S.1.2.

S.1.4. **Control of critical steps & intermediate:**

As discussed in the point No. S.1.2.
S.2. Characterization :-

S.2.1. Elucidation of structure and other characteristics :-

S.2.1.1 Physicochemical Characterization :-

The vaccine contains 50 mcg of polysaccharide for each of the serogroup's (A, C, Y and W135) purified polysaccharide in a lyophilized form. Active Pharmaceutical Ingredient (API) of C, Y and W-135 serogroups is Sialic acid. Phosphate is an API for serogroup A. Lactose is used as a stabilizer.

Structures of the Capsular Polysaccharides of *Neisseria meningitidis* A, C, Y & W-135:-

<table>
<thead>
<tr>
<th>Group</th>
<th>Structure of repeating unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>→6)α-D-ManNAc(1-PO4→ 3 ↑OAc</td>
</tr>
<tr>
<td>C</td>
<td>→9)α-D-NeuNAc(2→ 7/8 ↑OAc</td>
</tr>
<tr>
<td>Y</td>
<td>→6)α-D-Glc (l→4) α-D-NeuNAc (2→ (OAc)</td>
</tr>
<tr>
<td>W135</td>
<td>→6)α-D-Gal (l→4) α-D-NeuNAc (2→ (OAc)</td>
</tr>
</tbody>
</table>

*N. meningitidis* group A polysaccharide consists of partly O-acetylated repeating units of N-acetylmannosamine, linked with 1alpha → 6 phosphodiester bonds.

*N. meningitidis* group C polysaccharide consists of partly O-acetylated repeating units of sialic acid, linked with 2 alpha → 9 glycosidic bonds.

*N. meningitidis* group Y polysaccharide consists of partly O-acetylated alternating units of sialic acid and D-glucose, linked with 2 alpha → 6 and 1 alpha → 4 glycosidic bonds.

*N. meningitides* group W135 polysaccharide consists of partly O-acetylated alternating units of sialic acid and D-galactose, linked with 2 alpha → 6 and 1 alpha → 4 glycosidic bonds.

O-acetyl content, Sialic acid content, Nucleic acid, protein content and phosphorus content are analyzed by biochemical assay to detect chemical structure of Meningococcal Polysaccharides with the help of UV spectrophotometer.


Analytical testing performed to characterize the purified polysaccharide lot of Meningococcal Polysaccharide Vaccine (Group A, C, Y & W135) are follows :-

- Nucleic acid content determination
- Protein content determination
- O-acetyl content determination
- Moisture content determination
- Sialic acid content determination
- Phosphorus content determination
- Identity test
- Molecular size
- pH
- Free formaldehyde
- Cetrimide
- Sterility
- Pyrogens

S.2.1.2 Biological Characterization:

Each purified polysaccharide lot is tested for identity by rocket immuno electrophoresis and sterility by direct inoculation method.

S.2.2. Impurities:

The impurities such as protein, nucleic acid and bacterial endotoxins were removed during the purification process of the Purified Polysaccharide lot.

S.3. Control of Drug substance:

S.3.1. Specification:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Quality Control Test</th>
<th>Specifications as per Indian Pharmacopoeia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Moisture content</td>
<td>The loss on drying or moisture content is determined by thermogravimetry method and is used to calculate the results of the chemical tests of purified polysaccharide with reference to the dried substance.</td>
</tr>
<tr>
<td>2.</td>
<td>Protein content</td>
<td>Each lot of purified polysaccharide shall contain not more than 10mg of protein per gram of purified polysaccharide for Groups A and C organisms and less than 50 mg of protein per gram of polysaccharide for Group Y and W135.</td>
</tr>
<tr>
<td>3.</td>
<td>Nucleic acid content</td>
<td>Each lot of purified polysaccharide shall contain not more than 10 mg of nucleic acid per gram of purified polysaccharide, calculated with reference to the dried substance.</td>
</tr>
<tr>
<td>4.</td>
<td>O-acetyl content</td>
<td>The O-acetyl content of the polysaccharide shall be not less than 2.0 mmol of O-acetyl groups per gram of purified polysaccharide for Group A, not less than 1.5 mmol per gram of purified polysaccharide for Group C, not less than 0.3 mmol per gram of polysaccharide for Groups Y and W135, all calculated with references to the dried substance.</td>
</tr>
<tr>
<td>5.</td>
<td>Phosphorus content</td>
<td>Not less than 80 mg of phosphorus per gram of group A purified polysaccharide, calculated with reference to the dried substance.</td>
</tr>
<tr>
<td>6.</td>
<td>Sialic acid content</td>
<td>Not less than 800 mg of sialic acid per gram of Group C polysaccharide and not less than 560 mg of sialic acid per gram of purified polysaccharide for Group Y and W135, all calculated with reference to the dried substance.</td>
</tr>
<tr>
<td>7.</td>
<td>Molecular size</td>
<td>Atleast 65% of Group A, 75% of Group C polysaccharide, 80% of the Group Y and W135 polysaccharides shall be eluted before a distribution coefficient (KD) of 0.5 is reached.</td>
</tr>
<tr>
<td>8.</td>
<td>Test for serological identity and specificity</td>
<td>Each lot shall be tested for serological identity /specificity. The presence of group specific antigen(s) shall be confirmed.</td>
</tr>
<tr>
<td>9.</td>
<td>Sterility test</td>
<td>If no evidence of microbial growth is found, the preparation under examination complies with the test for sterility.</td>
</tr>
<tr>
<td>10.</td>
<td>Calcium content</td>
<td>After 15 minutes, any opalescence in the test solution is not more intense than that in the standard.</td>
</tr>
<tr>
<td>11.</td>
<td>pH</td>
<td>The pH value of Purified Polysaccharide lot of Meningococcal polysaccharide lot shall be 7± 0.5.</td>
</tr>
<tr>
<td>12.</td>
<td>Free Formaldehyde</td>
<td>0.2 g/l is the maximum Free Formaldehyde in purified polysaccharide lot of Meningococcal polysaccharide vaccine. The test sample should be not more intense in colour than reference solution.</td>
</tr>
<tr>
<td>13.</td>
<td>Cetrimide</td>
<td>Yellow precipitate formed in standard solution and there should be no precipitation in test sample.</td>
</tr>
<tr>
<td>14.</td>
<td>Pyrogens</td>
<td>If the sum of difference between maximum and initial temperature of three rabbits is less than 1.4°C and if response of individual rabbit is less than 0.6°C, the preparation being examined passes the test.</td>
</tr>
</tbody>
</table>

**S.3.2. Stability:**

Stability study at real time (at or below -20°C) and accelerated condition (2-8°C) was carried out on three lots of purified polysaccharide lot (bulk) of Meningococcal Polysaccharide Vaccine. The conditions of study and number of batches considered are satisfactory.

From the result of stability study it was concluded that the drug substance was found to be stable in real time (at or below -20°C) and accelerated condition (2-8°C). Hence, shelf life of 5 years was assigned for the purified polysaccharide lot under recommended storage conditions (at or below -20°C).

**P. Drug product (name, Dosage form) :-**

**P.1. Manufacturer (name, Dosage form) :-**

**P.1.1. Manufacturer(s) (name, dosage form) :-**

BIO-MED (P) LTD.  
C-96, Site No. 1,  
Bulandshahr Road Industrial Area,  
Ghaziabad - 201 009 (U.P.) INDIA  
Phone : 0120-4157534, 4204862  
Fax : 0120-4340219  
e-Mail : bmvaccine@yahoo.com  
Website: www.biomed.co.in
P.1.2. Batch formula :-

The formulated vaccine Quadri Meningo™ (Meningococcal Polysaccharide Vaccine) is in freeze dried form and batch formula is given below:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Ingredients</th>
<th>Quantity per dose (0.5 ml) or single dose presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Purified Polysaccharide of <em>Neisseria meningitidis</em> Group A</td>
<td>50 µg</td>
</tr>
<tr>
<td>2</td>
<td>Purified Polysaccharide of <em>Neisseria meningitidis</em> Group C</td>
<td>50 µg</td>
</tr>
<tr>
<td>3</td>
<td>Purified Polysaccharide of <em>Neisseria meningitidis</em> Group Y</td>
<td>50 µg</td>
</tr>
<tr>
<td>4</td>
<td>Purified Polysaccharide of <em>Neisseria meningitidis</em> Group W135</td>
<td>50 µg</td>
</tr>
<tr>
<td>5</td>
<td>Lactose I.P. (Stabilizer)</td>
<td>5 mg</td>
</tr>
<tr>
<td>6</td>
<td>Thimerosal I.P. (Preservative)</td>
<td>0.05 mg</td>
</tr>
</tbody>
</table>

P.1.3. Description of Manufacturing process & process control

**PRODUCTION FLOW DIAGRAM OF MENINGOCOCCAL POLYSACCHARIDE VACCINE FINAL LOT**

<table>
<thead>
<tr>
<th>Manufacturing Process</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purified Polysaccharide lot stored at or below -20°C.</td>
<td></td>
</tr>
</tbody>
</table>
| Preparation of final bulk by aseptic dilution with sterile normal saline, so as to content 50 microgram per dose of Polysaccharide (s). | pH control  
Sterility |
| Containerization, visual inspection of final containers, labeling, packing, storage (2-8oC) | Volume control  
Temperature control  
Humidity control |
| Final lot of Meningococcal Polysaccharide vaccine (Group A,C,Y &W135) | Identification  
Assay (Concentration of polysaccharide)  
Sterility  
Pyrogens  
Abnormal toxicity  
Molecular Size  
Water  
Antimicrobial Preservative  
PH |
P.1.4. Control of critical steps & intermediate (name, dosage form)

PRODUCTION FLOW DIAGRAM OF MENINGOCOCCAL POLYSACCHARIDE VACCINE FINAL LOT

<table>
<thead>
<tr>
<th>Manufacturing Process</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purified Polysaccharide lot stored at or below -20°C.</td>
<td></td>
</tr>
<tr>
<td>Preparation of final bulk by aseptic dilution with sterile normal saline, so as to content 50 microgram per dose of polysaccharide(s).</td>
<td>pH control • Sterility</td>
</tr>
<tr>
<td>Containerization, visual inspection of final containers, labeling, packing, storage (2-8°C)</td>
<td>Volume control • Temperature control • Humidity control</td>
</tr>
<tr>
<td>Final lot of Meningococcal Polysaccharide Vaccine (Group A,C,Y &amp; W135) I.P.</td>
<td>Identification • Assay (Concentration of polysaccharide) • Sterility • Pyrogens • Abnormal toxicity • Molecular Size • Water • Antimicrobial Preservative • pH</td>
</tr>
</tbody>
</table>

P.2. Control of excipients:-

P.2.1. Excipients of Human or Animal Origin (name, dosage form):

There is no use of excipient of human or animal origin for the manufacture of Meningococcal Polysaccharide Vaccine.

P.3. Control of Drug Product:-

P.3.1. Specification(s):

For Final Bulk:-

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Quality Control Test</th>
<th>Specifications as per Indian Pharmacopoeia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Sterility</td>
<td>If no evidence of microbial growth is found, the preparation under examination complies with the test for sterility.</td>
</tr>
</tbody>
</table>
For Final Lot:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Quality Control Test</th>
<th>Specifications as per Indian Pharmacopoeia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Identification</td>
<td>Purified monospecific polysaccharide shall be shown to be serologically identical &amp; specific.</td>
</tr>
<tr>
<td>2.</td>
<td>Assay (Concentration of polysaccharide)</td>
<td>Meningococcal polysaccharide vaccine shall contain the declared content (50 µg/dose) of each Group-specific polysaccharide (s) ± 30%, using the purified polysaccharide (s) incorporated in the vaccine as a reference.</td>
</tr>
<tr>
<td>3.</td>
<td>Sterility</td>
<td>If no evidence of microbial growth is found, the preparation under examination complies with the test for sterility.</td>
</tr>
<tr>
<td>4.</td>
<td>Pyrogens</td>
<td>If the sum of difference between maximum and initial temperature of three rabbits is less than 1.4°C and if response of individual rabbit is less than 0.6°C, the preparation being examined passes the test.</td>
</tr>
<tr>
<td>5.</td>
<td>Abnormal Toxicity</td>
<td>The test vaccine passes the test if none of the animals dies or shows signs of ill health in 7 days following the injection. If more than one animal die, the preparation fails the test. If one of the animals dies or shows the signs of ill health, repeat the test. The test sample passes the test if none of the animals in the second test dies or shows any signs of ill health in the time interval specified.</td>
</tr>
<tr>
<td>6.</td>
<td>Molecular Size</td>
<td>The vaccine complies with the test for molecular size if kD for the principal peak not greater than 0.70 for Group A and Group C polysaccharide, not greater than 0.57 for Group Y Polysaccharide, not greater than 0.68 for Group W135 polysaccharide.</td>
</tr>
<tr>
<td>7.</td>
<td>Water</td>
<td>The average residual moisture content of freeze dried final lot vaccine shall be not greater than 3%.</td>
</tr>
<tr>
<td>8.</td>
<td>Antimicrobial Preservative</td>
<td>Preservative content shall be between 0.0085% to 0.0115% per dose of 0.5 ml.</td>
</tr>
<tr>
<td>9.</td>
<td>pH</td>
<td>The pH of final lot of reconstituted Meningococcal Polysaccharide Vaccine I.P. shall be 7 ± 0.5</td>
</tr>
</tbody>
</table>
P.3.2. **Container Closure System (name, dosage form):**

Various material used for the final packing of vaccine are as follows.

- **Glass Vials:**
  2ml and 5 ml, 13 mm USP type I clear tubular glass vial for single and multi-dose.

- **Rubber closures:**
  13 mm Grey Butyl Slotted Rubber Stopper (Sterile ready for use).

- **Aluminium Seals:**
  13 mm flip off GN-17 aluminium seals.

Materials used for the final packing of vaccine diluent are as follows:

- **Glass vial:**
  2ml and 5 ml, 13 mm USP type I clear tubular glass vial for single and multi-dose diluent.

- **Rubber Closures:**
  13 mm Grey butyl, ’Bioclean RFU’ Rubber stopper.

- **Aluminium Seals:**
  13 mm flip off white (WE1) aluminium seals.

P.4. **Stability:**

P.4.1 **Stability Summary and Conclusion:**

Stability studies real time (2-8°C) and at accelerated condition (20-25°C and 30-35°C) have been conducted on three consecutive lots Meningococcal Polysaccharide Vaccine. The test results prove good stability of the product. Test specifications for release of final lot were met after storage at recommended storage condition (2-8°C) for at least 36 months. Based on the results of stability studies shelf life of 24 months was assigned for final lot of vaccine at recommended storage condition of +2 to +8°C.

P.4.2 **Post approval stability protocol and stability commitment (name, dosage form):**

Every year one batch of Quadri Meningo™ is subjected to real time stability study as per the approved protocol.
A. **Appendices** :-Module 3.2.A

A.1 **Details of equipment and facilities for production of drug product**

For Lay out of the facility used for manufacturing of Quadri Meningo™ and list of equipments refer to Module 3 Point No. 3.2.A.

A.2. **Adventitious Agents Safety evaluation (name, dosage form, manufacturer)** :-

**For non-viral adventitious agents :-**

The routine manufacturing control of adventitious agents, such as bacteria, mycoplasma and fungi, typically using well-established analytical procedure like sterility test.

Test for sterility is applied to pharmacopoeial articles that are required according to the pharmacopoeia to be sterile.

The test is designed to reveal the presence of micro-organisms in the sample used in the test; interpretation of the results of testing is based on the assumption that all units of an article or the entire bulk product or the contents of every container of the filled product in a lot or batch, had they been tested, would also have given the same results. Since all the units or the bulk or all the containers cannot be tested a sufficient number of samples of units or containers should be examined to give a suitable degree of confidence in the results of the tests.

Media used for the tests should comply with the growth promotion test. Fluid thioglycollate medium is primarily intended for the culture of anaerobic bacteria; however, it will also detect aerobic bacteria, soyabean-casein digest medium is suitable for the culture of both fungi and aerobic bacteria.

**For viral adventitious agents :-**

Meningococcal vaccine is a polysaccharide freeze dried vaccine therefore there is not found viral adventitious agents.

**Materials of Biological Origin :-**

There is no material of biological origin used in manufacturing of this product.